Renal cell carcinoma 4

Common Name(s)

Renal cell carcinoma 4

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma 4" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Renal cell carcinoma 4" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Renal cell carcinoma 4" returned 35 free, full-text research articles on human participants. First 3 results:

Cystic renal cell carcinoma: a report of 67 cases including 4 cases with concurrent renal cell carcinoma.
 

Author(s): Shanwen Chen, Baiye Jin, Liqi Xu, Guanghou Fu, Hongzhou Meng, Ben Liu, Jun Li, Dan Xia

Journal:

 

Cystic renal cell carcinoma (CRCC) is relatively rare; CRCC is frequently misdiagnosed as a benign renal cyst. CRCC carries an excellent prognosis following surgical treatment. The aim of our study was to summarize the management of CRCC and to characterize the prognosis of affected patients.

Last Updated: 15 Nov 2014

Go To URL
Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo.
 

Author(s): Guang-Hui Hu, Huan Liu, Peng Lai, Zhui-Feng Guo, Liang Xu, Xu-Dong Yao, Jun-Hua Zheng, Min Liu, Yun-Fei Xu

Journal:

 

The Delta-like ligand 4 (Dll4) and Notch signaling pathway plays a key role in embryonic vascular development and tumor growth. In this study, we measured the expression of Dll4 in clear cell renal cell carcinoma (ccRCC) and explored the correlation between Dll4 and ccRCC. We used ...

Last Updated: 26 Jun 2014

Go To URL
Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis.
 

Author(s): Qing Bo Huang, Xin Ma, Hong Zhao Li, Qing Ai, Shang Wen Liu, Yu Zhang, Yu Gao, Yang Fan, Dong Ni, Bao Jun Wang, Xu Zhang

Journal: Oncotarget. 2014 May;5(10):3066-75.

 

The Notch ligand Delta-like 4 (DLL4) plays an important role in tumor angiogenesis, which is required for tumor invasion and metastasis. Here we showed that DLL4 was elevated in endothelium and Notch signaling was activated in renal cell carcinoma (RCC). Exogenous DLL4 induced RCC ...

Last Updated: 16 Jun 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Renal cell carcinoma 4" returned 0 free, full-text review articles on human participants.

 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib
 

Status: Not yet recruiting

Condition Summary: Renal Cell Cancer

 

Last Updated: 28 Apr 2009

Go to URL
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
 

Status: Recruiting

Condition Summary: Metastatic Renal Cell Carcinoma

 

Last Updated: 24 Mar 2015

Go to URL
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
 

Status: Recruiting

Condition Summary: Non Small-cell Lung Cancer; Renal-cell Cancer; Gastrointestinal Stroma Tumor

 

Last Updated: 31 Aug 2014

Go to URL